Download PDF
CC BY-NC-ND 4.0 · Avicenna J Med 2022; 12(02): 093-096
DOI: 10.1055/s-0042-1749628
Case Report

Loperamide-Induced Ventricular Tachycardia Storm

William Giesing
1   Internal Medicine, Southern Illinois University School of Medicine, Illinois, United States
,
Cameron Koester
2   Department of Internal Medicine, Medical College of Wisconsin, Wisconsin, United States
3   Department of Cardiology, Medical College of Wisconsin, Wisconsin, United States
,
Mohammad Al-Akchar
4   Department of Internal Medicine, Southern Illinois University School of Medicine, Illinois, United States
5   Department of Cardiology, Southern Illinois University School of Medicine, Illinois, United States
,
Abhishek Kulkarni
4   Department of Internal Medicine, Southern Illinois University School of Medicine, Illinois, United States
5   Department of Cardiology, Southern Illinois University School of Medicine, Illinois, United States
,
Mohamed Labedi
4   Department of Internal Medicine, Southern Illinois University School of Medicine, Illinois, United States
5   Department of Cardiology, Southern Illinois University School of Medicine, Illinois, United States
› Author Affiliations Funding None.
› Further Information
   Permissions and Reprints

Abstract

Loperamide is an over-the-counter antilaxative medication with minor opioid properties. For this reason, it has recently become a drug of concern for the Food and Drug Administration due to its potential for abuse. In addition, further apprehension pertaining to its over-the-counter availability has developed due to the recent increase in reported cases of loperamide overdose or prolonged use leading to arrhythmias. We described a rare case of loperamide-induced ventricular tachycardia storm.

Keywords

loperamide - ventricular tachycardia storm - ventricular arrhythmias - opioid


Publication History

Article published online:
22 June 2022

© 2022. Syrian American Medical Society. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Wu PE, Juurlink DN. Clinical review: loperamide toxicity. Ann Emerg Med 2017; 70 (02) 245-252
    CrossrefPubMedGoogle Scholar
  • 2 Regnard C, Twycross R, Mihalyo M, Loperamide WilcockA.. J Pain and Symptom Manage. 2011; 42 (02) 319-323
    PubMedGoogle Scholar
  • 3 Sawalha K, Abozenah M, Kadado AJ. et al. Systematic review of COVID-19 related myocarditis: insights on management and outcome. Cardiovasc Revasc Med 2021; 23: 107-113
    CrossrefPubMedGoogle Scholar
  • 4 Battisha A, Sawalha K, Altibi AM, Madoukh B, Al-Akchar M, Patel B. Cardiogenic shock in autoimmune rheumatologic diseases: an insight on etiologies, management, and treatment outcomes. Heart Fail Rev 2022; 27 (01) 93-101
    CrossrefPubMedGoogle Scholar
  • 5 Zaman J, Agarwal S. Management of ventricular tachycardia storm. Heart 2021; 107 (20) 1671-1677
    CrossrefPubMedGoogle Scholar
  • 6 Daniulaityte R, Carlson R, Falck R. et al. “I just wanted to tell you that loperamide WILL WORK”: a web-based study of extra-medical use of loperamide. Drug Alcohol Depend 2013; 130 (1-3): 241-244
    CrossrefPubMedGoogle Scholar
  • 7 Eifling M, Razavi M, Massumi A. The evaluation and management of electrical storm. Tex Heart Inst J 2011; 38 (02) 111-121
    PubMedGoogle Scholar
  • 8 Kamiya K, Niwa R, Morishima M, Honjo H, Sanguinetti MC. Molecular determinants of hERG channel block by terfenadine and cisapride. J Pharmacol Sci 2008; 108 (03) 301-307
    CrossrefPubMedGoogle Scholar